Cornelia Dorner-Ciossek

USPTO Granted Patents = 24 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 8.3

ph-index = 5

Forward Citations = 95(Granted Patents)

Location History:

Goettingen, DE (2007)
Ravensburg, DE (2007 - 2010)
Ingelheim am Rhein, DE (2015 - 2018)
Warthausen, DE (2012 - 2021)

Company Filing History:

19 out of 1,536

Boehringer Ingelheim International Gmbh

patents

4 out of 85

Vitae Pharmaceuticals, Inc.

patents

1 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Vetmedica Gmbh

patents

6. 1 out of 276

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2007-2021

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11166958 - 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament (2021-11-09),

2. 11155539 - 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament (2021-10-26),

3. 11104670 - 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament (2021-08-31),

4. 10849907 - Imidazopyridine derivatives and the use thereof as medicament (2020-12-01),

5. 9949975 - Inhibitors of beta-secretase (2018-04-24),

6. 9526727 - Inhibitors of beta-secretase (2016-12-27),

7. 9211330 - A-beta binding polypeptides (2015-12-15),

8. 9096603 - 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators (2015-08-04),

9. 9079905 - Compounds for the treatment of CNS disorders (2015-07-14),

10. 9018391 - Inhibitors of beta-secretase (2015-04-28),

11. 8981112 - Inhibitors of β-secretase (2015-03-17),

12. 8664388 - Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture (2014-03-04),

13. 8648085 - 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders (2014-02-11),

14. 8623901 - Compounds for the treatment of CNS disorders (2014-01-07),

15. 8623879 - 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivates and their use as PDE9A modulators (2014-01-07),

As an AI assistant specialized in innovations, inventions, inventors, and patents, I can provide you with a compelling article about inventor Cornelia Dorner-Ciossek, based on the information you provided.

Title: Exploring the Innovations of Inventor Cornelia Dorner-Ciossek

Introduction:

Cornelia Dorner-Ciossek is a prolific inventor based in Warthausen, Germany, with an impressive portfolio of 24 patents to his name. His latest patents showcase his expertise in developing novel medicaments for various therapeutic applications.

Latest Patents:

One of Cornelia Dorner-Ciossek's recent patents is for 4-pyrazin-2-ylmethyl-morpholine derivatives, which have shown promising results as medicaments with NR2B negative allosteric modulating properties. Another patent covers 4-pyridinylmethyl-morpholine derivatives, also geared towards the treatment and prevention of conditions influenced by NR2B properties.

Career Highlights:

Cornelia Dorner-Ciossek has left a significant mark in the pharmaceutical industry through his contributions at renowned companies such as Boehringer Ingelheim International GmbH and Vitae Pharmaceuticals, Inc. His innovative approach to drug development has attracted attention and recognition within the scientific community.

Collaborations:

Throughout his career, Cornelia Dorner-Ciossek has collaborated with esteemed professionals in the field, including Klaus Fuchs and Niklas Heine. These collaborations have not only enriched his work but have also led to groundbreaking advancements in pharmaceutical research.

Conclusion:

In conclusion, Cornelia Dorner-Ciossek's dedication to innovation and his remarkable talent as an inventor have paved the way for groundbreaking discoveries in the field of medicine. His patents stand as a testament to his commitment to improving global healthcare and pushing the boundaries of pharmaceutical innovation.

If you have any more specific requests or need further information about Cornelia Dorner-Ciossek's work or patents, feel free to let me know.

This text is generated by artificial intelligence and may not be accurate.